Etienne P.
- Country
- France
- Department
- Unité d’hématologie et de Thérapie Cellulaire
Research Overview
- Phase 1b Evaluation of CTPS1 Inhibitor STP938 in High-Risk Essential Thrombocythaemia Resistant or Intolerant to Hydroxycarbamide Therapy
- Evaluation of Luspatercept and Epoetin Alfa in Low-Risk Myelodysplastic Syndromes Without Ring Sideroblasts Post-Erythropoiesis-Stimulating Agent Failure
- Evaluation of Navitoclax Monotherapy and Combination with Ruxolitinib in Myeloproliferative Neoplasms: Safety, Tolerability, and Pharmacokinetics
Data & Insights
Has run more than one trial at 66 of 207 partner sites.
Specializations
Myelofibrosis Research
This investigator specializes in treating primary and secondary myelofibrosis, with particular focus on novel therapeutic approaches. Their expertise extends to managing post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.
- Advanced therapeutic combinations
- JAK inhibitor resistance management
- Spleen volume reduction strategies
Polycythemia Vera Studies
The investigator conducts research in polycythemia vera treatment, particularly focusing on JAK2V617F-positive high-risk cases. Their work includes evaluation of novel therapeutic agents for maintaining hematocrit control.
- Hematocrit management protocols
- Alternative treatment approaches
- Disease progression monitoring
Myeloid Disorders
Their research encompasses broader myeloproliferative neoplasms and myelodysplastic syndromes. The investigator has specific interest in treating low-risk myelodysplastic syndrome patients who have failed conventional therapies.
- Novel therapeutic agents
- Treatment resistance patterns
- Combination therapy approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.